Adolescents and young adults (AYA) 13 to 24 years old in the United States make up approximately 20% of all new HIV diagnoses and have some of the highest rates of sexually transmitted infections, highlighting the clear need for HIV prevention in this age group.1,2  Because there are many challenges to HIV prevention, it is important to consider youth-specific systemic interventions. Pre-exposure Prophylaxis (PrEP) is an essential component of the HIV prevention toolkit and an important component of the national “Ending the HIV Epidemic” (EHE) initiative and National HIV Strategy.

In this issue of Pediatrics, Kimball and colleagues describe estimates of adolescents prescribed PrEP. Using a national pharmacy database (the IQVIA Real world database), they evaluated changes in PrEP prescriptions for adolescents 13 to 19 years old between 2018 and 2021 by sex, age group, urban or rural setting, US region, and prescriber. The...

You do not currently have access to this content.